Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > VisEn Announces Launch of Novel MMPSense Fluorescence Molecular Imaging Probe

-VisEn's Expanding Probe Portfolio Broadens Molecular Imaging Applications in Key Areas of Disease Research and Drug Development-

VisEn Announces Launch of Novel MMPSense Fluorescence Molecular Imaging Probe

WOBURN, MA | Posted on June 8th, 2007

VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the market launch of its MMPSense(TM) molecular imaging probe for real time imaging of matrix metalloproteinase (MMP) related activities in vivo. The launch further expands the company's proprietary molecular imaging probe and system product platforms to now even more broadly enable real-time imaging of molecular and biologic activity in vivo, including ranges of protease activities, angiogenesis, bone generation, vascular permeability, and inflammatory responses. By imaging and quantifying disease-related biological activities and therapeutic interventions in vivo, VisEn technology platforms enable expanded areas of research, increasingly efficient drug development, and advanced personalized clinical medicine into the future.

The VisEn MMPSense(TM) probe, developed from the Company's proprietary fluorescence imaging probe platforms, is an activatible in vivo fluorescence probe capable of imaging MMP activity in tumors and other sites of inflammation in vivo. In its non-active state, the probe is not fluorescent, but it emits strong fluorescence in response to MMP activity in vivo. According to the National Cancer Institute, MMPs are a group of enzymes that can break down proteins, such as collagen, that are normally found in the spaces between cells in tissues (i.e., extracellular matrix proteins). It is known that MMP activity is involved in many disease-related phenomena, including cancer propagation, invasion and metastasis, inflammation, host response, and in areas of cardiovascular disease. On May 2 of this year, VisEn Medical and its exclusive distribution partner in Asia, Olympus Corporation, announced the launch of MMPSense as well as VisEn's nanoparticle- based AngioSpark and AminoSpark molecular imaging probes, in Japan and other key Asian markets.

"Today's MMPSense product launch marks a significant advance in our drive to provide a complete package of translational molecular imaging solutions for measuring and quantifying disease progression and drug effect in vivo," said Kirtland G. Poss, President and CEO of VisEn Medical. "Our partners in drug development and clinical research worldwide can now access these important new tools that will help the whole field better understand, define and treat molecular targets and disease processes in an unprecedented fashion."

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Probe Portfolio and its Fluorescence Molecular Tomographic Imaging Systems (FMT), provide the industry's most robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers in vivo. VisEn probes are designed to be compatible with a range of fluorescence imaging systems, including planar fluorescence imaging systems, intravital microscopes, and VisEn's FMT tomographic imaging system.

Additional product information can be obtained by calling Customer Support at VisEn Medical: 781-932-6875, ext. 315; or via email at: ; or at .


About VisEn Medical, Inc.
VisEn Medical, Inc. was founded in 2000 based on fluorescence imaging technologies initially developed by industry-leading researchers and clinicians at the Massachusetts General Hospital and Harvard Medical School. VisEn is developing the industry's highest performing fluorescence molecular imaging technology platforms, from research through medicine. The Company also works directly with its partners to design ranges of tailored probes and applications that are targeted to their specific research areas. VisEn recently announced a multi-year joint research and development program with Merck & Co to develop and apply a range of fluorescence imaging agents for real-time imaging of key disease biomarkers in vivo. Privately-held VisEn is headquartered in Woburn, Massachusetts and has been financed by leading venture firms including Flagship Ventures and The Bollard Group.

For more information, please click here

Customer Support
VisEn Medical
781-932-6875, ext. 315

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016

Nanosciences: Genes on the rack October 21st, 2016

Nanoparticle vaccinates mice against dengue fever October 21st, 2016

Tiny gold particles could be the key to developing a treatment for pancreatic cancer October 19th, 2016


Precise quantum cloning: possible pathway to secure communication: Physicists create best ever quantum clones October 26th, 2016

The quantum sniffer dog: A laser and detector in 1: A microscopic sensor has been developed at TU Wien, which can be used to identify different gases simultaneously October 25th, 2016

Hybrid nanostructures hold hydrogen well: Rice University scientists say boron nitride-graphene hybrid may be right for next-gen green cars October 25th, 2016

New method increases energy density in lithium batteries: Novel technique may lead to longer battery life in portable electronics and electrical vehicles October 24th, 2016


Nanosciences: Genes on the rack October 21st, 2016

Smashing metallic cubes toughens them up: Rice University scientists fire micro-cubes at target to change their nanoscale structures October 20th, 2016

EM Resolutions announce the availability of Kleindiek Nanotechnik’s new cryo microgripper for cryo-FIB lift-out October 18th, 2016

The University of Applied Sciences in Upper Austria uses Deben tensile stages as an integral part of their computed tomography research and testing facility October 18th, 2016

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project